A Turning Point for Obesity:
WHO’s New GLP-1 Guideline
Dr. José M. Zuniga, President/CEO, Fast-Track Health
On December 1, 2025, the World Health Organization (WHO) issued its first global guideline on the use of GLP-1 therapies for adults living with obesity. This guideline is not just clinical guidance, but a call for a paradigm shift in how we treat obesity: from a “lifestyle issue” to a chronic, relapsing disease that demands comprehensive care, prevention, and equity.
For too long, programs and policies addressing obesity have among other things privileged simple “eat less, move more” messaging and ignored that obesity arises from a complex interplay of genetics, neurobiology, environment, social determinants, commercial forces, and structural inequities. WHO’s new guideline is a jolt to that complacency, inviting health systems to treat obesity as the chronic disease it is and deploy modern pharmacology in combination with behavioral, preventive, and health-system approaches.
In plain terms, the WHO recommends adults living with obesity may use GLP-1 therapies for long-term treatment (defined as ≥6 months), but the recommendation is conditional. Second, for people receiving GLP-1 therapy, WHO recommends pairing medication with intensive behavioral therapy (IBT), notably structured support around diet, physical activity, counseling, goal setting, monitoring, and lifestyle changes. Again, conditional, due to limitations in long-term data and implementation evidence. Underlying both recommendations is the recognition that obesity is a chronic, relapsing disease requiring lifelong care, not a failure of willpower or isolated choice.
In short, GLP-1 drugs are a powerful new tool but only one part of a broader, person-centered, sustainable obesity care ecosystem. However, they offer an opportunity to help reverse the course of a global public health crisis. More than 1 billion people worldwide live with obesity; by 2030, that number could double. Obesity is not only a driver of heart disease, diabetes, and kidney disease, but also threatens to overwhelm health systems, erode healthy life expectancy, and deepen inequities. The availability of effective therapy could fundamentally change trajectories for many.
Urban environments are at the epicenter of the obesity epidemic. Rapid urbanization has outpaced the development of healthy food systems, walkable neighborhoods, green spaces, and affordable recreational infrastructure. Many cities – particularly in low- and middle-income countries – face a collision of risk factors: ultra-processed food saturation, aggressive marketing from commercial food actors, sedentary work patterns, and chronic exposure to pollution that worsens metabolic disease. Any global response must recognize that cities concentrate both the drivers of obesity and the opportunities to reverse them.
Yet the obesity epidemic is not exclusively urban. Peri-urban areas, often overlooked in public health planning, face some of the most acute vulnerabilities. These communities sit at the margins of cities, where land-use patterns are rapidly changing and health systems are often underdeveloped. Food deserts and food swamps proliferate in these zones, where cheap calories are abundant but nutritious foods are scarce, and where transportation barriers limit access to both healthy foods and healthcare. Peri-urban residents often fall through the cracks of urban and rural policy frameworks alike, making targeted approaches essential.
Rural areas, too, experience obesity through distinct pathways: limited healthcare access, scarcity of specialists, long distances to services, economic insecurity, and reduced availability of fresh, affordable foods. The simplistic narrative that rural lifestyles are inherently “healthier” masks structural inequities that fuel obesity. Chief among these are declining agricultural livelihoods and the consolidation of food supply chains dominated by ultra-processed products. If global health strategies fail to address obesity through these multiple geographic lenses – urban, peri-urban, and rural – they will miss the complexity of the epidemic and the communities most affected by it.
As with most global public health challenges, we must call for strengthening health systems to deliver evidence-based obesity management across the continuum of care. To make GLP-1 therapy useful at scale, countries must invest in primary care platforms, supply-chain capacity, trained providers, monitoring systems, registries, referral networks – the full backbone of a chronic-care infrastructure. This aligns squarely with the kind of health systems strengthening approach that Fast-Track Health champions. It also means embedding obesity care into universal health coverage (UHC) frameworks and prioritizing access for high-risk and underserved populations.
WHO acknowledges critical obstacles: high costs, limited production capacity, supply-chain constraints, intellectual property/patent and licensing barriers, and health-system readiness deficits. Without policies like generic licensing, tiered pricing, pooled procurement, local manufacturing, inclusion in essential-medicines lists, and integration into public health platforms, GLP-1 therapies risk becoming yet another commodity accessible only to privileged populations while the most vulnerable remain sidelined. That is why this guideline is less about celebrating a breakthrough innovation and more about launching a global systems-transformation agenda.
At Fast-Track Health, we actively push for disruptive, systemic approaches to global health – beyond disease silos, beyond emergencies, toward resilient, equitable health ecosystems. The new WHO GLP-1 guideline offers exactly such a disruptive inflection point.
- GLP-1 therapies and the broader wave of metabolic therapies now under development can become anchor innovations, catalyzing investment, political will, and attention toward obesity and noncommunicable diseases (NCDs).
- Deployment at scale requires robust primary care, supply chains, financing mechanisms, and care platforms; the same elements that strengthen systems for HIV, NCDs, maternal/child health, and more.
- A commitment to equity demands that newer therapies do not deepen disparities. We can push for inclusion of GLP-1 therapies in UHC benefit packages, support generic or tiered models, and advocate for equitable access.
- Obesity care should be part of a life-course, whole-system framework, in essence encompassing upstream drivers (food systems, urban design, social determinants), prevention, early detection, treatment, and long-term follow-up.
- A shift from “blame and shaming” to “chronic disease + care + justice” is an opportunity to reframe obesity, overweight, and metabolic disease in global public health, destigmatize, and build solidarity.
But caution must guide our optimism. WHO’s recommendations are conditional, not a blanket guarantee. Long-term data remain limited: how will GLP-1 therapies perform on kidney health, cognitive outcomes, quality of life over decades? What happens if treatment is discontinued? Moreover, cost, supply, equity, and health-system readiness are major constraints. Without real commitment from governments, industry, and global health funders, the promise of pharmacological innovation could remain out of reach for those who need it most.
Finally, drugs are not a magic bullet. Unless paired with robust behavioral, social, environmental interventions – healthy food systems, urban planning, social protection, prevention policies – GLP-1 therapies alone cannot stop the obesity epidemic. The publication of WHO’s guideline is a signal that the global community is now equipped (theoretically) to treat obesity as a chronic disease, with modern therapy, clinical care, and system-level commitment. But a signal alone does not change outcomes. Now is the moment for bold, coordinated action.
Source: Celletti F, Farrar J, de Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-1 Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. Published online December 1, 2025. doi: 10.1001/jama.2025.24288